Skip to main content
TYK Medicines, Inc logo

TYK Medicines, Inc — Investor Relations & Filings

Ticker · 2410 ISIN · CNE100006L34 HKEX Manufacturing
Open in API
Filings indexed 869 across all filing types
Latest filing 2026-02-03 Share Issue/Capital Cha…
Country HK Hong Kong
Listing HKEX 2410

About TYK Medicines, Inc

https://www.tykmedicines.com

TYK Medicines, Inc. is a clinical-stage biopharmaceutical company specializing in the discovery, development, and commercialization of innovative small-molecule targeted therapies. The company leverages a proprietary small molecule drug design and screening platform, with a primary strategic focus on oncology, particularly treatments for lung cancer. The lead pipeline asset, TY-9591 (Edotamidine mesylate), an EGFR-targeted therapy, is currently in the Pre-NDA stage, having demonstrated promising clinical efficacy in treating lung cancer patients with brain metastasis. The pipeline also includes assets such as TY-302 and TY-2136, alongside multiple CDK inhibitors in clinical development, reflecting a commitment to addressing unmet medical needs in targeted cancer treatment.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 January 2026
Share Issue/Capital Change Classification · 100% confidence The document is a 'Monthly Return for Equity Issuer' filed with the Hong Kong Stock Exchange. This specific form is used by listed companies to report monthly movements in their securities, including changes in share capital, issued shares, and treasury shares. According to the provided filing definitions, announcements regarding share issues, capital changes, or movements in securities fall under the 'Share Issue/Capital Change' (SHA) category.
2026-02-03 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2026
Regulatory Filings Classification · 95% confidence The document is a 'Monthly Return for Equity Issuer' filed with the Hong Kong Exchanges and Clearing Limited (HKEX). This is a standard regulatory filing required by the HKEX Listing Rules to report monthly movements in securities, share capital, and public float. It does not represent a specific corporate event like a dividend announcement, M&A, or earnings release, but rather a routine regulatory disclosure of share capital status. Therefore, it falls under the 'Regulatory Filings' category.
2026-02-02 English
VOLUNTARY ANNOUNCEMENT - INCLUSION OF ASANDEUTERTINIB (TY-9591) IN THE LIST OF PRODUCTS FOR PRIORITY REVIEW BY THE CENTER FOR DRUG EVALUATION OF THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION
Regulatory Filings Classification · 98% confidence The document is a voluntary announcement issued by TYK Medicines, Inc. regarding the inclusion of their drug, Asandeutertinib (TY-9591), in the List of Products for Priority Review by the NMPA. It does not fit into specific categories like financial reports, dividend notices, or director dealings. As it is a general regulatory announcement regarding business developments and product status, it falls under the 'Regulatory Filings' (RNS) category.
2026-01-29 English
INSIDE INFORMATION - ISSUANCE OF FILING NOTICE BY THE CSRC FOR THE H SHARE FULL CIRCULATION APPLICATION OF THE COMPANY
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the issuance of a filing notice by the CSRC for an 'H Share Full Circulation' application. It details the regulatory approval process for converting unlisted shares into H shares. This falls under capital structure changes and regulatory updates. Since it is an announcement of a regulatory event rather than a financial report or a specific share issuance event (like a new offering), it is best classified as a general regulatory filing.
2026-01-23 English
VOLUNTARY ANNOUNCEMENT - THE COMPANY HAS BEEN GRANTED THE DRUG MANUFACTURING LICENSE BY THE DRUG ADMINISTRATION OF ZHEJIANG PROVINCE
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement issued by TYK Medicines, Inc. regarding the receipt of a Drug Manufacturing License (DML) from the Drug Administration of Zhejiang Province. It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor is it a report publication announcement (RPA) as it contains the substantive news itself. Since it is a general regulatory announcement regarding business operations that does not fall into the other specialized categories, it is classified as a Regulatory Filing (RNS).
2026-01-23 English
VOLUNTARY ANNOUNCEMENT - PROPOSED INCLUSION OF ASANDEUTERTINIB (TY-9591) IN PRIORITY REVIEW&#x3b; AND UNUSUAL PRICE AND TRADING VOLUME MOVEMENTS
Regulatory Filings Classification · 98% confidence The document is a voluntary announcement issued by TYK Medicines, Inc. regarding business developments (priority review for a drug) and a response to unusual price and trading volume movements. It does not fit into specific categories like financial reports, dividends, or director dealings. As it is a general regulatory announcement regarding company operations and market activity, it falls under the 'Regulatory Filings' category.
2026-01-07 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.